Evidence map›Paper›PMID 35906435›Full record

ArticleCommunity mental health journal2023

Perspectives Regarding Medications for Opioid Use Disorder Among Individuals with Mental Illness.

Derjung M Tarn, Kevin J Shih, Allison J Ober, Sarah B Hunter, Katherine E Watkins, Jeremy Martinez, Alanna Montero, Michael McCreary, Isabel Leamon, John Sheehe and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Community mental health journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 86% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Derjung M TarnDepartment of Family Medicine, University of California, Los Angeles, Los Angeles, CA, USA. dtarn@mednet.ucla.edu.ORCID http://orcid.org/0000-0001-7426-6387
Kevin J ShihDepartment of Family Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Allison J OberRAND Corporation, Santa Monica, CA, USA.
Sarah B HunterRAND Corporation, Santa Monica, CA, USA.
Katherine E WatkinsRAND Corporation, Santa Monica, CA, USA.
Jeremy MartinezLA County Department of Mental Health, Los Angeles, USA.
Alanna MonteroDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA, USA.
Michael McCrearyDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA, USA.
Isabel LeamonRAND Corporation, Santa Monica, CA, USA.
John SheeheLA County Department of Mental Health, Los Angeles, USA.
Elizabeth BromleyDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA, USA.
University of California, Los Angeles · USRAND Corporation · USLos Angeles County Department of Mental Health · US

Funding

Developing Capacity for Opioid Use Disorder Treatment in Mental HealthR34DA046950 · NIDA · RAND CORPORATION · PI OBER, ALLISON · 2018 to 2020
$801k
NIDA NIH HHS R34 DA046950NIDA NIH HHS R34DA046950
6 · The paper itself

Abstract

Most people with co-occurring opioid use disorder (OUD) and mental illness do not receive effective medications for treating OUD. To investigate perspectives of adults in a publicly-funded mental health system regarding medications for OUD (MOUD), we conducted semi-structured telephone interviews with 13 adults with OUD (current or previous diagnosis) receiving mental health treatment. Themes that emerged included: perceiving or using MOUDs as a substitute for opioids or a temporary solution to prevent withdrawal symptoms; negative perceptions about methadone/methadone clinics; and viewing MOUD use as "cheating". Readiness to quit was important for patients to consider MOUDs. All participants were receptive to discussing MOUDs with their mental health providers and welcomed the convenience of receiving care for their mental health and OUD at the same location. In conclusion, clients at publicly-funded mental health clinics support MOUD treatment, signaling a need to expand access and build awareness of MOUDs in these settings.

Indexed as

BuprenorphineOpioid-Related DisordersAdultAnalgesics, OpioidHumansMethadoneOpiate Substitution TreatmentAnalgesics, OpioidBuprenorphineMethadoneBuprenorphine-naloxone drug combinationMental disordersNarcotic antagonistsOpioid-related disordersOpioid use disordersQualitative research

Identifiers

PMID35906435
PMCPMC9859922
OpenAlexW4288715342

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.